DRUG

Riluzole

Amyotrophic lateral sclerosis (FDA 1995)

73 hypotheses across 10 therapeutic domains

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

Riluzole appears in hypotheses across 10 disease domains: ALS, Alzheimer, Depression, Epilepsy, Glioblastoma, Inflammatory bowel disease, Multiple sclerosis, Pancreatic cancer, Rheumatoid arthritis, Type 2 diabetes. Shared mediators that recur across at least two of those domains: MMP-9, MMP-2, EAAT2, p53, TDP-43, CK1δ.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for Riluzole

ALS 6

Mediator Outcome Score Tier Lit. status Trial
TDP-43 FTLD 0.312 High partial evidence none
TDP-43 Alzheimer's disease 0.269 Mid reproduces known completed
TDP-43 neurodegeneration 0.269 Mid reproduces known completed
TDP-43 frontotemporal dementia 0.269 Mid reproduces known none
TDP-43 neuronal dysfunction 0.269 Mid partial evidence none
TDP-43 neurodegenerative diseases 0.269 Mid reproduces known completed

Alzheimer 4

Mediator Outcome Score Tier Lit. status Trial
CK1δ tau aggregation 0.269 Mid novel signal none
EAAT2 Alzheimer's disease 0.269 Mid reproduces known completed
MMP-9 Alzheimer's disease 0.269 Mid reproduces known completed
EAAT2 dementia 0.208 Mid reproduces known completed

Depression 5

Mediator Outcome Score Tier Lit. status Trial
MMP-9 major depressive disorder without recent suicide attempt 0.208 Mid novel signal none
MMP-9 branching of excitatory neurons 0.208 Mid novel signal none
MMP-9 recent suicide attempt 0.208 Mid novel signal none
MMP-9 perineuronal net 0.208 Mid novel signal none
MMP-9 inhibitory input to excitatory neurons 0.208 Mid novel signal none

Epilepsy 9

Mediator Outcome Score Tier Lit. status Trial
MMP-9 epilepsy 0.416 High reproduces known none
TDP-43 Hippocampal sclerosis 0.269 Mid partial evidence none
MMP-9 seizures 0.269 Mid reproduces known none
MMP-2 epilepsy 0.208 Mid reproduces known none
ATM autism 0.208 Mid reproduces known completed
PI3K/AKT PNES 0.208 Mid novel signal none
MMP-9 synaptic connectivity 0.208 Mid partial evidence none
MMP-9 poor prognosis 0.208 Mid reproduces known none
MGMT progression-free survival 0.208 Mid partial evidence none

Glioblastoma 3

Mediator Outcome Score Tier Lit. status Trial
MMP-9 glioblastoma invasiveness 0.208 Mid novel signal none
MMP-9 recurrence or progression 0.208 Mid novel signal none
EAAT2 glioma-associated epilepsy 0.208 Mid novel signal none

Inflammatory bowel disease 8

Mediator Outcome Score Tier Lit. status Trial
MMP-9 ulcerative colitis 0.312 High novel signal none
p53 architectural distortion 0.208 Mid novel signal none
MMP-9 colonic epithelial permeability 0.208 Mid novel signal none
MMP-9 Paris Classification 0.208 Mid novel signal none
p53 dysplasia 0.208 Mid novel signal none
MMP-9 colitis severity 0.208 Mid novel signal none
MMP-2 Crohn's disease 0.208 Mid novel signal none
p53 colorectal neoplasia risk 0.208 Mid novel signal none

Multiple sclerosis 6

Mediator Outcome Score Tier Lit. status Trial
EAAT2 multiple sclerosis relapse 0.269 Mid novel signal none
MMP-9 HHV-6 seropositivity 0.208 Mid novel signal none
MMP-9 Multiple Sclerosis 0.208 Mid reproduces known active
EAAT2 EDSS score 0.208 Mid partial evidence none
MMP2 relapse-remitting multiple sclerosis 0.208 Mid novel signal none
MMP-2 Multiple Sclerosis 0.208 Mid reproduces known active

Pancreatic cancer 17

Mediator Outcome Score Tier Lit. status Trial
CK1δ bladder cancer 0.269 Mid novel signal none
ATM recurrence 0.269 Mid partial evidence active
ATM recurrence 0.269 Mid partial evidence active
CK1δ pancreatic cancer 0.269 Mid partial evidence none
p53 lysophospholipid levels 0.208 Mid novel signal none
p53 pancreatic intraepithelial neoplasia 0.208 Mid novel signal none
MMP-2 histopathological type of cancer 0.208 Mid novel signal none
p53 early recurrence 0.208 Mid novel signal none
MMP-2 inflammation 0.208 Mid reproduces known completed
p53 recurrence distance to celiac axis 0.208 Mid novel signal none
MMP-2 female gender 0.208 Mid partial evidence active
MMP-2 perineural invasion 0.208 Mid novel signal none
p53 high-grade PanIN 0.208 Mid novel signal none
p53 successful PDX engraftment 0.208 Mid novel signal none
MMP-9 pancreatic cancer 0.208 Mid partial evidence none
MMP-2 inflammation 0.208 Mid reproduces known completed
MMP2 pancreatic adenocarcinoma 0.208 Mid novel signal none

Rheumatoid arthritis 6

Mediator Outcome Score Tier Lit. status Trial
MMP-9 rheumatoid arthritis 0.269 Mid partial evidence none
MMP-9 forced vital capacity 0.208 Mid reproduces known none
MMP-9 incident ILD 0.208 Mid novel signal none
MMP-9 cartilage matrix destruction 0.208 Mid novel signal none
MMP-9 RA 0.208 Mid partial evidence none
MMP-9 prevalent ILD 0.208 Mid novel signal none

Type 2 diabetes 9

Mediator Outcome Score Tier Lit. status Trial
MMP-2 brachial 24-h pulse pressure 0.208 Mid novel signal none
MMP-2 central 24-h pulse pressure 0.208 Mid novel signal none
MMP-2 office pulse pressure 0.208 Mid novel signal none
MMP-2 cardiovascular events 0.208 Mid novel signal none
MMP-2 retinopathy 0.208 Mid partial evidence none
p53 T2DM 0.208 Mid novel signal none
MMP-2 all-cause mortality 0.208 Mid partial evidence none
MMP-2 albuminuria 0.208 Mid novel signal none
MMP-2 pre-hypertension 0.208 Mid novel signal none

Clinical trials

100 registered trials for Riluzole

Source: ClinicalTrials.gov

← All drugs